Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the safety and effectiveness of pirtobrutinib LOXO-305 compared to ibrutinib in adults with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The study includes participants who may or may not have received prior treatment for their cancer and focuses on those with specific genetic markers, like 17p deletions, in one part of the trial. This is a phase 3, open-label study sponsored by Loxo Oncology, Inc. Participants receive either pirtobrutinib or ibrutinib as oral treatments. The study has two parts Part 1 compares pirtobrutinib and ibrutinib in a broad group of participants and may last up to six years, while Part 2 evaluates pirtobrutinib alone in treatment-nafve participants with 17p deletions for up to two years. Treatments are taken by mouth, and participants are randomly assigned to treatment groups. During the study, participants will undergo regular assessments to monitor their response to treatment, including checking for complete or partial remission. Researchers will evaluate progression-free survival, overall survival, duration of response, and tolerability over several years. Safety and effectiveness are closely tracked with scheduled visits and tests until data cutoff or disease progression. Participation can last up to six years depending on the study part.
Actively Recruiting
Researchers are studying an experimental drug called odronextamab combined with chemotherapy in patients with Diffuse Large B-cell Lymphoma DLBCL. This includes adults with untreated DLBCL as well as those whose disease has returned or not responded to treatment. The study aims to evaluate the safety, dosing, and effectiveness of odronextamab plus chemotherapy compared to the current standard treatment, rituximab combined with chemotherapy. The study is divided into Part 1A and 1B, which focus on determining safe doses and schedules of odronextamab combined with chemotherapy drugs including cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone. Part 2 is a randomized comparison where participants receive either odronextamab plus chemotherapy or rituximab plus chemotherapy. Odronextamab and rituximab are given by intravenous infusion, with rituximab also possibly given subcutaneously. Participants will be monitored for side effects, disease progression, and quality of life over time. Assessments include measuring drug levels in the blood, immune response to the drug, and physical functioning questionnaires. The study will follow participants for up to five years to evaluate progression-free survival and other outcomes. Safety and adverse events will be tracked for up to two years.
Actively Recruiting
Researchers are evaluating whether adding zilovertamab vedotin to the standard treatment can help people with previously untreated diffuse large B-cell lymphoma DLBCL live longer without their cancer growing or spreading. This phase 3 randomized study compares the combination of zilovertamab vedotin with rituximab plus cyclophosphamide, doxorubicin, and prednisone R-CHP against the standard treatment of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP. Participants receive treatments in 21-day cycles for up to six cycles approximately four months. One group receives zilovertamab vedotin with rituximab or its biosimilar, cyclophosphamide, doxorubicin, and prednisone or similar steroids, while the other group receives rituximab or its biosimilar, cyclophosphamide, doxorubicin, vincristine, and prednisone or similar steroids. Both groups may receive up to two additional cycles of rituximab or its biosimilar as decided by the investigator. During the study, participants will have regular assessments including imaging scans and heart function tests to monitor their health and response to treatment. Researchers will measure how long participants live without disease progression, overall survival, response rates, and quality of life up to several years. Safety is monitored by tracking adverse events and treatment discontinuations. The study lasts several years, with primary outcome assessments up to about 50 months and overall survival monitored up to approximately 74 months.
Actively Recruiting
Researchers are evaluating an experimental drug called odronextamab combined with lenalidomide for adults with relapsed or refractory Follicular Lymphoma FL or Marginal Zone Lymphoma MZL, which are subtypes of Non-Hodgkins Lymphoma NHL. This Phase 3 study includes two parts Part 1 to assess safety and dosing of the combination, and Part 2 to compare its effectiveness and safety against the current standard treatment of rituximab plus lenalidomide. The combination of odronextamab and lenalidomide is a first-in-human treatment being explored in this trial. In Part 1, participants receive odronextamab with lenalidomide to evaluate safety and determine dosing. In Part 2, participants are randomly assigned to receive either odronextamab plus lenalidomide or rituximab plus lenalidomide followed by lenalidomide alone, allowing comparison between the new combination and standard care. Both treatment combinations are administered according to the study protocol. Participants will be monitored for side effects, treatment tolerability, and disease progression through scheduled assessments including imaging scans and laboratory tests. Researchers will measure drug levels in the blood, immune responses against odronextamab, and quality of life impacts using questionnaires. Safety monitoring continues for up to two years, while efficacy outcomes such as progression-free survival and response duration are followed for up to five years, with ongoing evaluations throughout the study period.
Actively Recruiting
Researchers are investigating whether patients with locally advanced cervical cancer who still have detectable cell-free human papillomavirus DNA cfHPV-DNA in their plasma after standard treatment may benefit from additional chemotherapy. This trial is a prospective, randomized, multicenter clinical study designed to evaluate adjuvant chemotherapy based on this biomarker. The study focuses on patients who have undergone chemoradiotherapy and have persistent cfHPV-DNA, as this may indicate ongoing disease activity. Participants first receive standard treatment with concomitant chemoradiotherapy, including doses of radiation and weekly cisplatin. Four weeks after completing this treatment, a blood test is conducted to detect cfHPV-DNA in plasma. Patients with positive cfHPV-DNA results are randomly assigned to either receive two additional cycles of adjuvant chemotherapy with cisplatin and gemcitabine or to be monitored without further chemotherapy. Patients in both groups undergo regular follow-up every four months, including plasma cfHPV-DNA testing, CT scans of the chest, MRI scans of the abdomen and pelvis, and clinical and gynecological exams. During the study, participants are closely monitored for progression-free survival, overall survival, treatment response, quality of life, and any toxic effects of treatment. Follow-up assessments occur at regular intervals from 7 to 120 days after treatment. The total duration of participant involvement varies based on follow-up schedules. The study uses a single-blind design and randomized allocation to ensure scientific rigor while maintaining patient safety throughout the trial period.
Actively Recruiting
Researchers are conducting the TARSILA Study to evaluate the real-world effectiveness of maternal RSVpreF vaccination during pregnancy in Brazil. The study aims to measure how well this vaccine protects infants against respiratory syncytial virus RSV-associated acute respiratory illness ARI, including lower respiratory tract disease, by comparing infants with and without RSV infection. Two linked studies will take place one involving hospitalized infants and another involving infants treated as outpatients. The study includes two prospective, test-negative case-control designs conducted in Southern Brazil. The TARSILA Inpatient Study enrolls infants hospitalized for ARI, while the TARSILA Outpatient Study enrolls infants seen in outpatient healthcare settings for similar illnesses. Maternal vaccination status during pregnancy is recorded based on the Brazilian National Immunization Programs recommendations, focusing on vaccination between 240 to 366 weeks of gestation, with vaccination received at least 14 days before delivery. RSV testing is done using RT-qPCR on nasal swabs to classify infants as RSV-positive cases or RSV-negative controls. Participants are infants born in Brazil, up to 360 days old, meeting specific ARI symptom criteria. Data collection includes structured interviews with mothers and medical record reviews to assess vaccination status and other factors. Outcomes measured include hospitalization for lower respiratory tract disease and occurrence of acute respiratory illness in infants up to 180 days old. Enrollment runs from April 2026 to September 2028, with follow-up assessments based on clinical presentations and testing results.